Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/STROKEAHA.115.008851 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Firsekibart in acute gouty arthritis.
J Transl Med
January 2025
Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
ADMET-AI Enables Interpretable Predictions of Drug-Induced Cardiotoxicity.
Circulation
January 2025
Stanford Cardiovascular Institute (S.M., R.V.S., P.D.P., J.C.W.), Stanford University, CA.
Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
Oral Oncol
January 2025
School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China; Department of Otolaryngology Head and Neck Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing 210019, Jiangsu, China. Electronic address:
Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
Oral Oncol
January 2025
School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China; Department of Otolaryngology Head and Neck Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing 210019, Jiangsu, China. Electronic address:
Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation.
Asia Pac J Ophthalmol (Phila)
January 2025
Peking Union Medical College Hospital, Beijing, China. Electronic address:
Purpose: To evaluate the efficacy, durability and safety of intravitreal faricimab versus aflibercept over 48 weeks in patients with neovascular age-related macular degeneration (nAMD) from the LUCERNE China subpopulation.
Design: LUCERNE (NCT03823300) was a phase 3 global, double-masked, active comparator-controlled trial. The China subpopulation comprised patients from mainland China, Taiwan and Hong Kong.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!